Conditions:
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.
The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.
Dates: January 2009 -
Study Status: Recruiting
Ages Eligible: 21 Years - 65 Years
Gender Eligible: Both
Inclusion Criteria:
Exclusion Criteria:
Sponsor:
Phase: Phase 3
First Received: August 28, 2008
Last Updated: Oct 08, 2009
Clinicaltrials.gov ID:
NCT00744055
Study HIC # 0801003450
Conditions:
Intervention: Drug: Prazosin
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.
The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.
Dates: January 2009 -
Study Status: Recruiting
Ages Eligible: 21 Years - 65 Years
Gender Eligible: Both
Inclusion Criteria:
1. Males and females between the ages of 21-65 years old.
2. Current alcohol dependence, as determined by a structured clinical interview
(Structured Clinical Interview for DSM-IV Axis I Disorders) (SCID) (First et al.
1996).
3. Current PTSD as determined by the Clinician Administered PTSD Scale for DSM-IV(CAPS)
(Blake et al. 1995).
4. Patients with current alcohol dependence, with at least one recent episode of heavy
drinking (defined as 5 or more drinks per drinking episode) over the past 14 days.
5. Medically and neurologically healthy on the basis of history, physical examination,
EKG, screening laboratories (CBC w/ differential, TSH, Free-T4, ASAT, ALAT, GGT, BUN,
creatinine, calcium, phosphorous, magnesium, total protein, albumin, electrolytes,
VDRL, urinalysis, beta-HCG).
6. For women, negative pregnancy test and use of acceptable method of contraception.
Exclusion Criteria:
1. Females who are pregnant or lactating.
2. Individuals with a current unstable medical condition such as neurological,
cardiovascular, endocrine, renal, liver, or thyroid pathology (LFT 5 times normal,
abnormal BUN and creatinine, and unmanaged hypertension with BP more than 200/120)
which in the opinion of the physician would preclude the patient from fully
cooperating or be of potential harm during the course of the study.
3. Patients who meet current SCID criteria for the following major Axis I diagnoses
(Bipolar Disorders, Schizophrenia and Schizophrenia-type Disorders).
4. History of substance dependence (other than alcohol, cocaine, tobacco or cannabis) by
DSM-IV criteria in the last 30 days.
5. Individuals taking mood stabilizers and antipsychotic medications.
6. Individuals with a history of sensitivity to quinazolines or prazosin.
7. Individuals taking medications thought to influence alcohol consumption (naltrexone,
disulfiram, acamprosate).
8. Individuals taking adrenergic medication (e.g. clonidine).
9. Agents that may interact with prazosin such as drugs with CNS depressant effects
including tizanidine and xyrem.
Sponsor:
Phase: Phase 3
First Received: August 28, 2008
Last Updated: Oct 08, 2009
Clinicaltrials.gov ID:
NCT00744055
Study HIC # 0801003450
Elizabeth Ralevski, Ph.D.
203-932-5711 Ext. 4282
elizabeth.ralevski@yale.edu
Petrakis, Ismene Leonida
Principal Investigator
HIC # 0805003779
©
Yale School of Medicine
Privacy policy Site editor
